Oncopharmpod
TILs, Olutasidenib, T-DXd
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:17:52
- Mas informaciones
Informações:
Sinopsis
Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice. Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1). A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.
